oxalomalic-acid has been researched along with Disease-Models--Animal* in 1 studies
1 other study(ies) available for oxalomalic-acid and Disease-Models--Animal
| Article | Year |
|---|---|
Oxalomalate reduces expression and secretion of vascular endothelial growth factor in the retinal pigment epithelium and inhibits angiogenesis: Implications for age-related macular degeneration.
Clinical and experimental observations indicate a critical role for vascular endothelial growth factor (VEGF), secreted by the retinal pigment epithelium (RPE), in pathological angiogenesis and the development of choroidal neovascularization (CNV) in age-related macular degeneration (AMD). RPE-mediated VEGF expression, leading to angiogenesis, is a major signaling mechanism underlying ocular neovascular disease. Inhibiting this signaling pathway with a therapeutic molecule is a promising anti-angiogenic strategy to treat this disease with potentially fewer side effects. Oxalomalate (OMA) is a competitive inhibitor of NADP Topics: Angiogenesis Inhibitors; Animals; Cell Line; Cell Movement; Cell Proliferation; Disease Models, Animal; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Macular Degeneration; Mice; Oxalates; Reactive Oxygen Species; Retinal Pigment Epithelium; Signal Transduction; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2016 |